The products are ChAdOx1 from Oxford and the Serum Institute of India, and Moderna’s mRNA-1469. They target Bundibugyo virus, responsible for the current outbreak.
The trial is led by the Congolese National Institute of Biomedical Research. It recruits contacts of patients through a ring vaccination strategy. The announcement concerns further clinical evaluation; it does not yet demonstrate the two products’ effectiveness against this outbreak.